Houston, TX, United States of America

Federica Pericle

USPTO Granted Patents = 5 

Average Co-Inventor Count = 2.6

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2009-2012

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovator Federica Pericle: Pioneering Cancer Treatment Solutions

Introduction

Federica Pericle is a distinguished inventor based in Houston, TX (US). She has made significant contributions to the field of cancer treatment, holding a total of five patents. Her innovative work focuses on the use of lactoferrin in combating malignant neoplasms and other hyperproliferative diseases.

Latest Patents

Among her latest patents, one notable invention is titled "Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases." This invention relates to methods of treating hyperproliferative diseases by administering a composition of lactoferrin, either alone or in combination with standard anti-cancer therapies. Another significant patent is "Lactoferrin as an adjuvant in cancer vaccines," which outlines methods of treating cancer by administering a composition of lactoferrin in conjunction with cancer vaccines.

Career Highlights

Federica Pericle is currently associated with Agennix Incorporated, where she continues to advance her research and development efforts in cancer therapies. Her work has garnered attention for its potential to improve treatment outcomes for patients suffering from various forms of cancer.

Collaborations

She collaborates with esteemed colleagues, including Atul Varadhachary and Rick Barsky, who contribute to her research endeavors and help drive innovation in the field.

Conclusion

Federica Pericle's contributions to cancer treatment through her innovative patents highlight her role as a leading inventor in the medical field. Her work continues to inspire advancements in therapeutic approaches for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…